ProblemSleep centers still find out too late that tonight's PSG or HSAT was never clear to run: prior auth is pending, the insurer wanted HSAT first, chart qualifiers are missing, or the referral expired. That burns scarce lab slots and stretches diagnosis timelines.
SolutionSleepFlow ingests the schedule, chart, and payer status, then flags false-ready studies before staff start chasing portals. It focuses on the ugly handoff between referral, authorization, modality rules, and a truly runnable sleep study.
Market opportunityAASM says nearly 30 million Americans have sleep apnea and about 80% remain undiagnosed, while Future Market Insights sizes the sleep-study market at $7.5B in 2026. Buyers already pay for PSG software, yet readiness still lives in spreadsheets and phone calls.